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Introduction
Mental illness is common among HIV-infected
individuals. Outpatient studies of un-incarcerated HIV-infected patients reveal a prevalence as
high as 54% for Axis I psychiatric disorders
(major depression, bipolar disorder, schizophrenia and obsessive compulsive disorder) and
26% for Axis II psychiatric disorders (personality disorders).1 Among the incarcerated, data
from the United States (US) Bureau of Justice
Statistics indicate that over 16% of all state
prison and jail inmates have a mental or emotional condition, 10% receive psychotropic medication and 12.5% participate in mental health
therapy or counseling.2 Given the high prevalence of psychiatric disorders among those with
HIV infection, as well as among the incarcerated, it is likely that a significant proportion of HIVinfected inmates are suffering from one or more
mental illnesses.
Mental illness complicates the management of
HIV infection in several ways. First, studies
have shown that mental illnesses, especially
depression, contribute to treatment non-adherence and poor HIV outcomes.3 Second,
patients with mental illness are less likely to be
prescribed certain treatments including hepatitis
C virus (HCV) therapy and highly-active antiretroviral therapy (HAART) in many settings,4
despite new data suggesting that patients with
mental illness who receive treatment for the
mental illness achieve HIV clinical outcomes
equal to or better than HIV-infected control

Providence, RI 02912

401.453.2068

patients without mental illness.5 Lastly, mental
illness, when sub-optimally treated, has been
associated with behaviors that risk transmission
of HIV. 6,7,8
A key to improving outcomes in HIV-infected
populations is adequate detection and treatment of mental illnesses. At the very minimum,
HIV providers should be familiar with the
screening and management of the most common mental illness among HIV-infected patients
- depression. Reviews on the management of
depression, including in HIV-infected patients,
have been recently published.6,9 In this article
we highlight diagnostic and therapeutic
approaches to depression among HIV-infected
incarcerated persons.
Screening for Depression
Despite the high prevalence of depression, this
disorder is under-diagnosed and under-treated.
A major challenge to the clinician is the differentiation between major depression and isolation,
demoralization and reactive states of grief and
loss associated with negative experiences including the diagnosis of HIV infection and/or
incarceration. In addition, establishment of a
diagnosis of depression is complicated by the
overlap between symptoms that could suggest
depression, but could also be secondary to HIV
disease or attendant opportunistic conditions.
Indeed, the differential diagnosis that must be
considered during the work-up of depressive
symptoms in the HIV-infected inmate is extensive, and is discussed in detail below.
Depression may manifest predominantly as
somatic complaints. Although readily ascribed
Continued on page 2

WHAT’S INSIDE
Editor’s Letter
Case Series
Mental Health 101
IDCR-o-GRAM
Save The Dates
In The News
Self-Assessment Test
fax: 401.863.6087

pg 3
pg 4
pg 7
pg 7
pg 8
pg 8
pg 9
www.IDCRonline.org

If you have any problems with this fax transmission please call 800.748.4336 or e-mail us at IDCR@corrections.net

January 2006
DEPRESSION
INMATE

IN THE

Vol. 9, Issue 1
HIV-INFECTED

(continued from page 1)
to underlying HIV disease, symptoms such
as abdominal pain, fatigue, insomnia, inexplicable muscle or visceral pain and atypical cardiac symptoms have been found to
be more likely due to depression than
advancing HIV disease, especially in
patients with relatively high CD4 T-cell
counts.10
Data among non-incarcerated
individuals suggest men and women with
depression present with similar complaints,
though women are more likely to report
anxiety, somatization, increased appetite,
increased weight, increased sleep and hostility.11
In the setting of HIV infection, screening for
depression can be aided by the use of
standardized scales. We have validated
two screening tools - the General Hospital
Questionnaire (GHQ) and the Beck
Depression Inventory (BDI) in HIV-infected
individuals. In a study of outpatients with
HIV infection, any patient who scored
above six points on the GHQ and above 14
points on the BDI was found to have a high
likelihood of major depression when evaluated by a psychiatrist.1 Thus, a patient who
breaches these thresholds on both instruments should be evaluated thoroughly to
determine the type of depressive illness he
or she is experiencing.
Patients with a complaint of depression
usually suffer from either endogenous
depression (also known as major depression), or reactive depression (also known
as adjustment disorder or demoralization).
A third diagnosis, dysthymia, is less common. Patients with major depression are
less able to experience pleasure from pleasurable stimuli, a state known as anhedonia, and in any given setting the patient will
be less able or unable to feel pleasure. A
simple analogy is that for patients with
major depression, the experience is as if
the electrical outlet is not connected to the
wires carrying the current - no matter what
you plug in or when you try it, there is no
power. In contrast, patients with a reactivetype depression are depressed about
something, and therefore can experience
pleasure when distracted from the circumstance or event that is upsetting. In this
instance, it is as if the electrical outlet is
controlled by a switch - when the switch is
off because the patient is in the depressing
setting (e.g., at home, in jail or prison, in the
HIV clinic, etc.), there is no power, but
when the switch is on because the patient
is distracted from the depressing setting,
the power flows normally.
In a very simple categorization, major

visit IDCR online at www.IDCRonline.org
depression is a brain disease in which the
ability to feel pleasure is broken in a pervasive and persistent manner, while adjustment disorders are psychological impairments in which the patient's meaningful
experiences of life's events and circumstances cause an understandable bad
mood.
Understanding this basic premise of major
depression allows for a greater understanding of the experience of life by a
depressed person. One may try to imagine
a life in which nothing felt good. Food does
not have much flavor, sleep is not restful,
friends and family bring no joy, sex is not
pleasurable and one's usual enjoyable
activities are no longer fun. Further, without pleasurable inputs allowing one to interpret one's actions as successful and uplifting, one quickly comes to expect that every
action will lead to either numbness or pain.
Hopelessness ensues. Major depression
driven suicide kills thousands of people
who have fallen to despair and have begun
to believe that nothing will ever go right
again. Of course, things do go right all the
time, but the depressed person cannot
experience the pleasure that other people
and life have to offer - to return to the analogy, it is as if the outlet has been disconnected from the electricity.
When assessing a patient with a complaint
of depression, it is therefore important to
ask about pleasurable experiences. In a
correctional setting, pleasurable experiences may be limited, but an interviewer
open to exploring a patient's daily routines
may discover several activities that result in
good feelings if the patient does not have
anhedonia (e.g., playing ball, talking with
friends, watching television, playing cards,
visiting with relatives/friends, reading, etc).
Furthermore, it is often very useful to obtain
input from an outside observer, when possible. If a patient will consent, the interviewer could contact a family member or
friend to determine how the patient appears
to feel when interacting with him or her
(e.g., on the phone, during a visit, etc).
It is likewise important to explore any of the
patient's interpretations of his or her
depression fully, without allowing the interviewer's attitudes about the complaint to
interfere. Such is the case, for example,
when a patient reports depression about
having HIV infection. Just because the
interviewer might feel it would be devastating to have HIV, one cannot assume the
patient shares those feelings exactly. For
many incarcerated individuals, being diagnosed with HIV was not the most devastating life experience that they have endured.
He or she may be reacting to an entirely dif-
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ferent aspect of the illness, or may be
reporting he or she is upset about the illness when nothing, in fact, has changed.
By saying the cause of the depression is
HIV-related, the patient may be trying to
explain depressive symptoms in an understandable way. Likewise, inmates may
attribute a host of depressive symptoms to
being incarcerated - restriction of activities
resulting in less pleasure, other inmates'
activities interrupting sleep, cafeteria food
taste causing loss of appetite, etc. In this
way, a major depressive episode could be
missed if the questions do not inquire
deeply enough about the experiences to
which negative feelings are attributed.
When major depression is diagnosed,
assessment should be made for suicidal
ideation (see Case #1 in this month's Case
Series). Assessment includes past mental
health history including prior suicide
attempts, symptoms of psychosis (voices
commanding the patient harm him/herself),
plans for suicide (patients with specific plan
for how to accomplish suicide are at greater
risk), beliefs regarding HIV disease progression and current life stressors.

Differential Diagnosis of Depression in
HIV-Infected Patients
Depressive symptoms in the HIV-infected
inmate may well indicate the presence of
major depression, but as CD4 T-cell count
decreases, concern for alternative infectious, metabolic and medication causes
increases.
The differential diagnosis
includes dementia, delirium, central nervous system (CNS) illnesses (e.g., lymphoma, toxoplasmosis, neurosyphilis, cryptocococcal meningitis), metabolic diseases
(e.g., hypothyroidism, hypogonadism),
acute medical illnesses, substance abuse,
cocaine withdrawal and medication side
effects (e.g., interferon, efavirenz, betablockers, metoclopramine), among others.
Infectious and opportunistic conditions can
be assessed as is appropriate given the
clinical stage of the patient and other suggestive symptoms and signs. In all patients
with depressive symptoms it is crucial to
examine for abnormalities of the thyroid
axis in men and women and testosterone
levels in men. Patients should be queried
for symptoms of these conditions and basic
laboratory studies should be done at least
annually to detect sub-clinical abnormalities. Correction of hypothyroidism and
hypotestosteronemia is often necessary to
achieve remission from major depression.12,13
In any case where major depression is suspected, probing for symptoms of bipolar
Continued on page 4
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Faculty Disclosure

EDITOR

Dear Corrections Colleagues,
A substantial proportion of persons living with HIV infection in the United States are incarcerated
and among these, many - if not the great majority - suffer from psychiatric illnesses. Mental illness
places people at risk for acquiring HIV and for those already HIV-infected, complicates treatment
and prevention efforts. As most of us have observed, abuse of alcohol, cocaine, heroin and other
illicit substances is often a form of self-treatment among the depressed and traumatized, increasing not only their odds for infection with HIV and viral hepatitis, but also for incarceration. In this
issue of the IDCR, Drs. Andrew Angelino and Glenn Treisman, psychiatrists leading Psychiatric
Services for the Johns Hopkins HIV/AIDS Care Program, provide a guide to the diagnosis and
treatment of the most prevalent mental health disorder of HIV-infected individuals - major depression. Drs. Angelino and Triesman have authored a useful book, "The Psychiatry of AIDS", available in paperback and a "must-read" for HIV health care providers - particularly those in corrections. Their article is complemented by a series of illuminating cases from Dr. Jeffery Watts,
Psychiatric Medical Director at the CORE Center, a large clinic specializing in mental health care
for HIV-infected patients which is associated with Cook County Hospital in Chicago.
I hope this issue, my first as editor, will raise awareness of the need to screen all HIV-infected
inmates for mental illnesses and provide a starting point for continued clinician education on the
detection and management of mental health disorders in correctional settings. Reading this issue
has made it clear to me that the benefits patients can accrue when their psychiatric illnesses are
addressed is multiple and includes improved quality of life, enhanced medical adherence, reduced
substance abuse and adoption of HIV transmission prevention measures. After reading this issue,
individuals should be able to differentiate between major depression and reactive states which can
produce depressive symptoms, appreciate the differential diagnosis of depression in the HIVinfected inmate and understand the approaches to the pharmacologic and psychotherapeutic treatment of depression in such patients.
In closing, I wish to thank you for the work you do, often in a difficult environment with patients who
do not always appreciate the value of the help you are offering. The IDCR staff, including the editorial board of experienced and insightful providers in correctional health care, aim to provide you
with the information you need to continue to deliver high quality care. During the next year we will
address topics most relevant to your work and will enhance our website to provide clinical
resources we hope you will find useful. We can best accomplish these aims with feedback from
you, our readers. Feel free to email me regarding the content of the IDCR at wohl@med.unc.edu.
Thanks,
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rated into the management of HCV infection.

(continued from page 2)
disease, specifically symptoms of mania,
should be performed given differences in
the management of these disorders.
There is some evidence that HIV infection
itself directly causes major depression.
First, there is a higher prevalence of major
depression in HIV-infected patients than in
the general population, as previously stated. Second, there is a correlation between
progression of HIV disease and development of major depression. This, taken in
concert with models for depression caused
by chronic CNS inflammation (likely mediated by both pro- and anti-inflammatory
cytokine action in CNS glial cells),14
demonstrates a possible causal relationship for HIV infection and major depression.
In addition to the direct effects of HIV and
inflammation on the brain causing major
depression, medications can cause or
worsen depression. Two medications in
particular, efavirenz and alpha-interferon15,16,17 (the latter used to treat HCV, frequently comorbid with HIV - particularly in
correctional settings) can cause depressive
symptomatology. In general, depressive
symptoms that begin after these medications are started should raise suspicion for
a causal relationship. This may be overlooked, however, since the depressive
symptoms often take some time to develop.
While the time course for efavirenz is less
clear, depressive symptoms develop
between one and 24 weeks after starting
treatment with alpha-interferon, with a
mean of eight to 12 weeks after first dose.
Screening for depression prior to initiation
of alpha-interferon and regularly during
therapy is prudent and should be incorpo-

Treatment
The best news for patients with major
depression from any cause is that it is usually a very treatable condition. In studies of
HIV-infected depressed patients, up to 85%
had at least some improvement with treatment within 12 weeks and 50% returned to
baseline.6,18 The overall response rate for
alpha-interferon-induced depression in the
literature is likewise approximately 85%.16
The cornerstone of effective treatment for
major depression is anti-depressant medication. All available standard anti-depressant therapies have a potential efficacy for
treatment of major depression co-morbid
with HIV and/or alpha-interferon therapy.
Selection of an agent is therefore based
primarily on tolerability. In general, antidepressants with few side effects experienced by the patient may promote adherence to the medications, and therefore,
may have a good chance at effective treatment. Treatment should be started at low
doses and titrated upward to minimize the
risk of adverse effects. An algorithm for the
management of depression and a listing of
variables to consider when prescribing an
antidepressant are shown in this month's
IDCR-o-gram.
As the efficacy of the various classes of
anti-depressants is similar, the search for a
good match between the patient and treatment can be informed by the properties of
the agents and the patient's medical and
psychiatric symptoms. For example, tricyclic anti-depressants, such as nortriptyline, doxepin and desipramine, often curb
diarrhea, promote sleep and assist with
weight gain - all of which may be desirable
for certain patients. Some selective serotonin-reuptake inhibitors (SSRIs) (e.g., flu-
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oxetine and escitalopram), venlafaxine XR,
bupropion SR and XL often cause some
activation, thus eliminating fatigue.
Bupropion SR may also be useful in combination with smoking cessation programs,
since it treats symptoms of nicotine withdrawal. Venlafaxime XR may reduce
chronic pain. Matching the side effect profile of the medication to the patient's presenting symptoms can be useful in promoting adherence, thus enhancing the likelihood of a therapeutic effect. An excellent
review of the properties of anti-depressants
has been recently published.9
An additional consideration when choosing
an anti-depressant for an HIV-infected
patient are interactions with current medications and those that are likely to be prescribed in the future.6 The IDCR published
a review of drug-drug interactions between
mental health and HIV medications in
January
2005,
available
at
www.IDCRonline.org.19 SSRIs, like many
protease inhibitors, are metabolized via the
cytochrome P450 system. Ritonavir, in particular, is an extremely potent inhibitor of
the P450 enzymes. Nevirapine can induce
the P450 system, producing relatively
decreased SSRI levels. Therefore, there is
a potential for drug interactions that can
alter SSRI levels; however, in general, the
majority of interactions between SSRIs and
antiretroviral fail to be clinically significant,
and this information is presented to alert
potential prescribers of a mechanism for
those rare cases of clinically-significant
interactions. Again, starting with lower
doses of the anti-depressant will reduce the
risk of supratherapeutic plasma drug levels
and adverse effects and permit titration to
doses that are tolerated and effective.
Following the initiation of anti-depressant
Continued on page 6

Mental Health Case Series
Jeffrey Watts, MD
Speaker's Bureau: BMS Virology, Abbott
Virology
Psychiatric Medical Director, CORE Center
Case # 1: Management of depression in
the HIV-infected patient
A 46 year-old African-American male coinfected with HIV and Hepatitis C virus
(HCV) presents for his routine medical
appointment. Incarcerated for the past
three years, he often reports sadness and

irritability, but has been reluctant to "take
another pill." He is prescribed a twice-daily
regimen of Combivir and Kaletra and has
achieved an undetectable viral load and
CD4 cell count of 750 cells/mm3. This
inmate has a past history of intravenous
"speedballing" of heroin and cocaine, but
denies prior psychotropic medication trials.
With the death of his mother three months
ago, he complains of a progression of his
depression with persistent low mood, frequent anger episodes, insomnia with early
morning awakening and passive thoughts

of dying. He seems despondent but sincere in his presentation and assertions of
safety. He is now agreeable to help, including medication, if necessary.
Case # 1: Questions
How would you manage his depression and
thoughts of dying? Does his current antiretroviral regimen impact the selection of
antidepressant or dosage?
Continued on page 5
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Case # 1: Discussion
The first consideration must be patient
safety. Many facilities would immediately
place this person on suicide precautions or
monitoring. However, past suicidal history,
current intent and/or plans to harm himself,
and his level of anxiety should be assessed
when devising the safety management
plan. Careful probing to determine each of
these can assist the provider in determining
whether or not the patient is currently a risk
to himself.
The next assessment centers on his
depression. Although bereavement is a
possibility in the differential diagnosis, the
extent and duration of his symptoms are
consistent
with
major
depression.
Treatment of major depression in HIV/AIDS
has been widely studied throughout the
AIDS epidemic. The estimate of the lifetime
prevalence of major depression in persons
with HIV is 50%, greatly exceeding that of
the general population. Medication management of depression usually results in
60-70% response within four to eight weeks
and remission in eight to 12 weeks.
Patients and clinicians alike often have
expectations
of
faster
outcomes.
Antidepressant selection in HIV/AIDS
patients is simpler than other psychotropic
classes. Most selective serotonin reuptake
inhibitors (SSRIs) and tricyclics (TCAs)
have shown similar efficacy and side effect
profiles to the general population. Although
mild interactions between ritonavir-containing regimens and some antidepressants
may occur, (generally leading to increased
levels of the antidepressants) most clinicians should feel comfortable and safe in
starting an antidepressant in this otherwise
stable HIV patient. Since efficacy is essentially equivalent in the spectrum of antidepressants, formulary availability and side
effect profiles usually dictate the selection.
Drug selection is less important than duration of treatment. Antidepressant medications should be continued for at least six to
nine months after remission of the depressive symptoms. The patient should be
monitored for the development of side
effects initially every two weeks and effectiveness of treatment assessed eight to 12
weeks after starting antidepressant therapy.
Continued follow-up every three to four
months thereafter is standard.
In addition to the challenge the dual diagnoses of HIV and major depression present
to this patient, as well as his clinicians, HCV
co-infection further complicates the situation. Interferon used in the treatment of
HCV infection can exacerbate depression.
However, a history of depression is not an
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absolute contraindication for HCV therapy
and patients with well controlled depression
may be candidates for such treatment in
coordination with a psychiatrist.
Case # 2: Management of co-morbid HIV
and severe mental illness
A 35 year-old Caucasian male has been a
frequent recidivist in the correctional setting
and is newly incarcerated. Diagnosed with
schizophrenia, his co-morbid cocaine
abuse and homelessness have contributed
to his recent HIV infection and diagnosis
prior to this incarceration. He has yet to
receive antiretroviral medications and is
unaware of any prior laboratory information.
Past corrections' records indicate various
psychotropic trials but the patient indicates
that he receives haloperidol (Haldol), carbamazepine (Tegretol) and benztropine
(Cogentin) from the local emergency room
when needed. He remembers having a
seizure after a head wound three years
ago, but denies any seizures since that
time. He currently has a flat affect and a
poverty of thought (e.g. speech is limited to
few words). Staff reports that he is paranoid
around other inmates over the past few
days. His last reported date of cocaine use
was two months ago.
Case #2: Questions
What is the recommended approach in the
treatment of severe mental illness in persons with HIV? What is the recommended
approach of antiretroviral treatment in the
severe mentally ill?
Case #2: Discussion
As always, the need for coordinated care
between psychiatry and HIV primary care is
essential. In these situations with two
severe disease processes, a prioritization
in treatment should follow the basic assessment of the mental illness (diagnosis, current symptoms, level of dysfunction, comorbid substance abuse) and HIV status
(viral load, CD4 count, current symptoms).
In this case, the patient's recent HIV infection would not likely need immediate antiretroviral medication; however he does
need immediate psychiatric treatment.
Although the psychiatrist would prescribe
the antipsychotic in this case, some important items are presented here. First, the
history and collaborative information would
be helpful to ensure the diagnosis of schizophrenia is correct. The current mental status exam and the remote last cocaine
usage make a cocaine-induced psychotic
disorder unlikely as the sole diagnosis. But
in patients with more recent cocaine exposure, this diagnosis must be considered.
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In regards to treatment, "typical" antipsychotics or "older" neuroleptics have a higher propensity for hyperprolactinemia, tardive dyskinesia, and extrapyramidal side
effects (EPS) including dystonias (involuntary muscle contractions), akithisia (restlessness, fidgeting) and parkinsonism. In
patients with HIV/AIDS, this rate may be
increased three-fold, reportedly due to the
predilection of the HIV virus for the basal
ganglia and associated areas of the brain.
Furthermore, medications to minimize EPS
symptoms such as diphenhydramine
(Benadryl) and benztropine (Cogentin)
often worsen cognitive functioning due to
the anticholinergic effects of these drugs.
Newer, or "atypical", antipsychotic medications are considered treatments of choice
for schizophrenia but may carry increased
risks of the metabolic syndrome with hyperlipidemia and/or non-insulin dependent diabetes mellitus (NIDDM). In particular, studies have most closely linked olanzapine
(Zyprexa) to these problems, although all
agents in this class carry the warning in
their package insert. The NIDDM is not
directly associated with the increase in
patient weight with the initiation of the drug.
One of the six atypical agents (Clozaril) can
cause agranulocytosis and is not usually
considered in HIV patients. Two of the
remaining five agents (Geodon and Abilify)
are CYP p450 3A4 substrates, which may
create challenges to future antiretroviral
management, particularly ritonavir-containing regimens. Risperidone (Risperdal) or
queitapine (Seroquel) might be the best
choices in this patient. Risperidone is now
available in a depot injection form
(Risperdal Consta) that may be administered every two weeks in non-adhering
patients. Due to the timing of antiretroviral
treatment, potential drug interactions, and
the need for metabolic monitoring (glucose/lipid), ongoing coordination between
the HIV provider and the psychiatrist will
continue to provide the best possible outcome for this patient.
Summary
The challenges in the management of mental illness and HIV in the correctional setting
may seem overwhelming. These cases
demonstrate that a thorough history, initial
physical examination and basic mental status assessment will provide you the needed
tools for diagnosis, initial management, and
psychiatric referrals. Although potential
drug interactions are overwhelming at times
to remember, the key to management and
monitoring is in coordination with knowledgeable pharmacists and psychiatrists to
ensure patient safety and positive patient
outcomes.
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therapy, the patient should be assessed
every two weeks initially, at first for monitoring of side effects and later for efficacy. It
may take six weeks to notice a significant
change in depressive symptoms and
patients should be counseled not to expect
rapid results. Once remission in depression is achieved, the dose of the antidepressant should not be altered.
Failure to achieve an effect should lead to
reassessment
of
the
diagnosis.
Suboptimal dosage, drug-drug interactions
and/or poor medication adherence may
have contributed to the failure. If these are
ruled-out, then a switch to another agent
can be attempted. Response rates to a
second SSRI after failure to respond to a
drug in this class are 60-70%.11 In cases
where a partial effect is seen during initial
anti-depressant therapy, the patient may be
a candidate for augmentation with a second
agent with a slightly different neuropharmacological profile (e.g., adding venlafaxine or
bupropion to an SSRI). There is a fair
amount of evidence suggesting that lithium
carbonate is an effective augmenting agent
which can be monitored by serum levels.20,21
Anti-psychotic medications are also very
useful in this regard. In particular, olanzapine22 promotes sleep and weight gain and
ziprazidone provides a nice "energy boost"
in lower doses (but must be taken with food
to be effectively absorbed in the stomach).23
All patients with treatment-resistant depression should be referred to a psychiatrist.
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It is important to remember that antidepressant medications themselves will
only affect a person's ability to feel pleasure. Psychotherapy is an integral part of
the treatment of major depression and is
more effective when combined with pharmacological therapy than when either is
used alone.24 Returning to the electric outlet analogy, anti-depressants will turn on
the power to the outlet. The patient's attitudes about the use of electric appliances
may be unaffected - he or she may believe
that life contains no pleasures or that pleasures are fickle and subject to disappear
without notice. This is the reason for combining psychotherapy with anti-depressant
medication. Psychotherapy is the process
of changing the patient's assumptions,
behaviors and feelings about the world
through discussion, exploration and practice. In essence, a depressed patient has
to gain insight that the experiences he or
she had while depressed were inherently
biased because of a brain disease disallowing the experience of pleasure, and that
new experiences, now that the power is
back on, will be different. In this way, trials
of behaviors once thought to be unrewarding may result in regained pleasures and
thus, generate a sense of hope.
Several clinical studies have demonstrated
enhanced efficacy of the treatment of
depression in HIV-infected patients with
psychotherapy25,26,27 and correctional systems with access to psychiatric consultation
and on-going appropriate counseling services for patients with major depression
have a distinct advantage in their ability to
treat this disorder. For patients who are
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about to be released, post-release community counseling and mental health care
should be arranged.
In all cases, there needs to be coordination
among HIV care providers and those providing psychiatric care to ensure that each
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dosage, potential for drug interactions and
the development of relevant treatmentrelated adverse effects.
Conclusion
HIV infection and major depression are
prevalent and often co-morbid conditions
among inmates in the U.S. Health care
providers practicing in the correctional setting are most effective when they can accurately diagnose and treat major depression
in HIV-infected inmates. Following the general principles in this article will assist
health care providers to diagnosis depression and differentiate between this disorder
and other conditions that can cause
depressive symptomatology, choose treatments that are tailored to the patient and
recognize the potential for toxicity and drug
interactions.
Psychiatric consultation
should be sought for patients with treatment-resistant depression, such as those
failing a second anti-depressant. In addition, psychotherapy is an important complement to pharmacologic therapy and should
be a component of the treatment of major
depression in the HIV-infected inmate.
Coordination between clinicians providing
HIV care and those providing psychiatric
care is essential to the safe and effective
management of shared patients.
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MENTAL HEALTH 101
Selection of a First Line Antidepressant Medication
Variable
Patient history
Age group
Children and adolescents
Adults < 65 yr
Adults > 65 yr
Family history of response
Past response

SSRI* (fluoxetine)
SSRI, NRI^ or SNRI**
SRI^^
Same medication that was effective in first-degree relative
Same medication that was effective previously

Depression characteristic

Mood stabilizer (lithium or lamotrigine) plus antidepressant
Antidepressant plus antipsychotic (atypical)
SSRI

Bipolar depression
Psychotic depression
Depression with features of
obsessive-compulsive disorder
Panic attacks
Agitated depression
Depression with psychomotor
retardation
Medication-resistant depression

^NRI norepinephrine-reuptake inhibitor
**SNRI = serotonin-norepinephrine
reuptake inhibitor
^^SRI serotonin-reuptake inhibitor.
Table adapted from:
Mann, J. Drug therapy: the medical
management of depression. NEJM.
2005; 353(17):1828.

SSRI
Sedating antidepressant
Nonsedating antidepressant (NRI, SSRI)
Electroconvulsive therapy or combination of medications

Coexisting medical conditions
Heart disease
Stroke
Pain

Nontricyclic antidepressants
Caution with SNRIs or NRIs and blood pressure
Duloxetine, venlafaxine

Concern regarding side effects
Gastrointestinal symptoms
Anticholinergic symptoms
Sexual dysfunction
Weight gain
Postural hypotension
Diabetes

IDCR-O-GRAM:

*SSRI = selective serotonin-reuptake
inhibitor

Medication

Nontricyclic antidepressant
Nontricyclic antidepressant
Non-SSRI antidepressant
Avoid atypical antipsychotics
NRI
Avoid atypical antipsychotics

HIV and Major Depression
Symptoms of Major Depression
Criteria for major depression or equivalent
or convincing other evidence of major depression

NO

YES

Psychotherapy
Antidepressant therapy with psychotherapy
drug selection paradigm

Tricyclic antidepressant as first drug
(Nortiptyline, Doxepin, Deslpramine) (There
are many others with special utility.)

Drugs with special or intermediary properties
(Trazodone, Netazodone, MAOIs,
Bupropion, Mirtazapine, Venlafaxine)

SSRI antidepressant as first drug (Fluoxetine,
Sertraline, Paroxetine, Fluvoxamine,
Escitalopram, Citalopram)

Tritherapeutic trial (usually 4-6 weeks)
If treatment fails or side effects intolerable change to new drug
(usually new class, but same class or augmentation if strong rationale)
With a partial response limited by maximum dose or toxicity:
Longer trial or augmentation strategy (lithium, neuroleptic,
thyroid hormone, second agent, etc.)
Table reprinted with permission from: Treisman G, Angelino A. The Psychiatry of AIDS: A Guide to Diagnosis and Treatment. 2004; 41

January 2006

Vol. 9, Issue 1

SAVE THE
DATES
Politics on Paper - Global
Tragedies/Personal Perils.
Featuring the work of Eric
Avery MD, John Risseeuw
and Robbin Ami Silverberg.
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13th Annual Conference on
Retroviruses and
Opportunistic Infections
February 5-9, 2006
Denver, Colorado
Visit:www.retroconference.org
13th Annual Ryan White
National Youth Conference
on HIV/AIDS
February 18-20, 2006
Philadelphia, Pennsylvania
Visit: www.napwa.org/rwnyc/
National Conference on
African-Americans and
AIDS
February 27-28, 2006
Philadelphia, PA
Visit: www.minority-healthcare.com/
NIMH/IAPAC Conference on
HIV Treatment Adherence
March 8-10, 2006
Jersey City, New Jersey
Visit: www.hivadherenceconference.com
Updates in Correctional
Health Care
April 8-11, 2006
Las Vegas, Nevada
Visit: www.ncchc.org
Satellite Videoconference
"Hepatitis B & C with HIV
Co-infection"
April 19, 2006
12:30-2:30 EST
CME-accredited webstream
of last conference available
on-line
Visit: www.amc.edu/patirnt/hiv
/hivconf/index.htm
ACHSA 2006
Multidisciplinary Training
Conference
May 11-13, 2006
Durham, North Carolina
Visit: www.achsa.org
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LITERATURE REVIEWS

Screening Tool for Mental Illness, Substance
Abuse Validated
Pence, et al conducted a validation study of the
Substance Abuse and Mental Illness Symptoms
Screener (SAMISS), a 16-item screening instrument designed to identify substance abuse and
mental illness in HIV-infected patients. The
Structured Clinical Interview for DSM-IV (SCID)
was used as the reference to evaluate the performance of the SAMISS in this study. The study population was comprised of HIV-infected patients who
had never previously been screened with the
SAMISS. Of 148 participants who completed follow-up, 37.2% screened positive on the SAMISS
substance abuse (SA) module. Compared with the
SCID, the SA module of the SAMISS had 86% sensitivity and 75% specificity. Of 143 participants who
completed SCIDs and complete data information,
69.2% screened positive on the mental illness (MI)
module of the SAMISS. Compared with the SCID,
the MI module of the SAMISS had 95% sensitivity
and 49% specificity. Study authors concluded that
the SAMISS demonstrated high sensitivity and
moderate specificity as a screening tool for the
identification of SA/MI in this HIV-infected patient
population. The brevity of the SAMISS makes it
practical for routine use in busy clinical settings, but
should be followed by a more rigorous psychiatric
evaluation for patients who screen positive.
Pence B, Gaynes B, Whetten K, et al. Validation of
a brief screening instrument for substance abuse
and mental illness in HIV-positive patients. J Acquir
Immune Defic Syndr. 2005; 40(4):434-44.
Clinician-Delivered Intervention to HIV Patients
Reduces Risk Behaviors
Fisher, et al conducted a prospective clinical trial to
evaluate the effectiveness of a clinician-delivered
intervention in reducing unprotected sexual behavior of HIV-infected patients. The risk reduction
intervention consisted of brief, patient-centered discussions, conducted during routine clinical visits,
over a study interval of 18 months. During these
discussions, clinician and patient negotiated an
individually tailored behavior change, goal or plan.
Sessions concluded with the patient being given a
"prevention prescription" written on a prescription
pad. Analysis of the intervention demonstrated that
unprotected vaginal, anal and insertive oral sexual
events decreased significantly over time among
HIV-infected patients who received the cliniciandelivered HIV prevention intervention. By contrast,
the same measures increased significantly over
time for HIV-infected patients in the standard-ofcare control arm. Study authors concluded that a
clinician-delivered HIV prevention intervention,
implemented during the course of routine clinical

care, can be effective in reducing a broad measure
of HIV-infected patients' unprotected vaginal, anal
and insertive oral sexual behavior.
Fisher J, Fisher W, Cornman D, et al. Cliniciandelivered intervention during routine clinical care
reduces unprotected sexual behavior among HIVinfected patients. J Acquir Immune Defic Syndr.
2006; 41(1):44-52.
Hospitalizations, Expenditures Due to HCV on
the Rise
As the population of patients infected with hepatitis
C virus (HCV) grows older, the treatment burden of
HCV continues to grow. Grant, et al sought to provide longitudinal statistics concerning health care
resource use by HCV-infected patients.
Hospitalization trends using the Nationwide
Inpatient Sample (NIS) from the Healthcare Cost
and Utilization Project (HCUP) were examined.
From 1994 through 2001, HCV-related hospitalizations, hospital days, total charges and deaths
increased at average annual rates exceeding 20%,
more than three-fold higher than rates for all-cause
hospitalizations. HCV liver causes for all ages
accounted for almost four times as many hospital
days in 2001 as in 1994. Increasing hospitalizations and hospital days coincided with higher
expenditures for HCV. Study authors concluded
that the future burden of HCV infection will match
and may exceed analysts' forecasts.
Grant W, Jhaveri R, McHutchinson J, et al. Trends
in health care resource use for hepatitis C virus
infection in the United States. Hepatology. 2005;
42(6):1406-13.
Antidepressant Treatment Improves Adherence
to ART
Untreated depression has been associated with
medication non-adherence. To evaluate the effect
of anti-depressant treatment (ADT) on antiretroviral
(ART) adherence, Yun, et al., retrieved data from
chart review for 1,713 HIV-infected patients seen at
an urban health care setting. Of these patients,
57% were depressed and of these, 46% and 52%
received ADT and ART treatment, respectively.
Adherence to ART treatment was lower among
depressed patients not adherent to ADT compared
to depressed patients adherent to ADT. Study
authors concluded that there may be a benefit of
ADT on ART adherence among depressed HIVinfected patients.
Yun L, Mavari M, Kobayashi J, et al. Antidepressant
Treatment Improves Adherence to Antiretroviral
Therapy Among Depressed HIV-Infected Patients.
JAIDS. 2005; 38(4):432-8.

RESOURCES
American Psychiatric Association.
http://healthyminds.org/copingwithaidsandhiv.cfm

Mental Health AIDS.
http://mentalhealthaids.samhsa.gov/index.asp

Centers for Disease Control and Prevention.
http://www.cdc.gov/hiv/pubs/brochure/care10.htm

National Institute of Mental Health.
http://www.nimh.nih.gov/publicat/dephiv.cfm

Information on Efavirenz:
Annals of Internal Medicine. 2005; 143(10):1-43.

National Institute of Mental Health.
http://www.nimh.nih.gov/publicat/index.cfm
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CONTINUING MEDICAL EDUCATION CREDIT

Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through February 28, 2006.
The estimated time for completion of this activity is one hour and there is no fee for participation.

1. HIV-infected patients with treated mental illnesses achieve
HIV outcomes equal to or better than those without psychiatric
disease. True or False?
A. True
B. False
2. Following initiation of antidepressant therapy…
A. the patient should be evaluated approximately every
four weeks initially to assess for adverse effects and
efficacy
B. if there is no response in four weeks therapy should be
modified
C. the dosage of the medication should be rapidly
increased to achieve maximal effect
D. if there is suboptimal response after six to eight weeks,
therapy can be switched to another agent
E. None of the above
3. The following statements regarding Major Depression are
TRUE:
A. A hallmark of the diagnosis is anhedonia
B. Patients with major depression can typically experience
pleasure when distracted from the situation they find
depressing
C. In some patients it may manifest as insomnia, weight
gain and hostility
D. A and B
E. A and C
4. Which of the following statements regarding treatment medications for depression is FALSE?
A. Doxepin may promote sleep and weight gain
B. Escitalopram often eliminates fatigue
C. Nortriptyline frequently causes diarrhea
D. All of the above
E. None of the above

IDCR EVALUATION
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
Main Article

educational value
5 4 3 2 1

clarity
5 4 3 2 1

In the News

5 4 3 2 1
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Save the
Dates
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2. Do you feel that IDCR helps you in your work?
Why or why not?

3. What future topics should IDCR address?

4. How can IDCR be made more useful to you?

5. Do you have specific comments on this issue?

5. Which of the following need to be assessed in all patients in
whom the diagnosis of major depression is considered?
A. Thyroid stimulating hormone
B. Testosterone level
C. Potential for suicidal ideation
D. Evidence of mania
E. All of the above
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